Search research articles
Contact Us
Filters
Showing results (41-50 of 92) with videos related to
Page
of 10
Sort By:
Lancet (London, England)
|
August 21, 2017
Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)
Jacob Schachter, Antoni Ribas, Georgina V Long, et al.
The Lancet. Oncology
|
June 22, 2019
Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study
Georgina V Long, Reinhard Dummer, Omid Hamid, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 21, 2022
COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients With <i>BRAF</i> V600-Mutant Melanoma
Reinhard Dummer, Keith T Flaherty, Caroline Robert, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 3, 2023
A Phase II Trial of the CD40 Agonistic Antibody Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Confirmed Disease Progression on Anti-PD-1 Therapy
Sarah A Weiss, Mario Sznol, Montaser Shaheen, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 23, 2019
Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management
Helen J Gogas, Keith T Flaherty, Reinhard Dummer, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 9, 2024
COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600E/K-mutant melanoma
Dirk Schadendorf, Reinhard Dummer, Keith T Flaherty, et al.
Nature Medicine
|
October 6, 2020
Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i
Reinhard Dummer, Celeste Lebbé, Victoria Atkinson, et al.
The Lancet. Oncology
|
July 27, 2019
Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study
Caroline Robert, Antoni Ribas, Jacob Schachter, et al.
JAMA Oncology
|
July 17, 2020
Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition With Pembrolizumab Outcomes in Advanced Melanoma: Pooled Analysis of 3 Clinical Trials
Igor Puzanov, Antoni Ribas, Caroline Robert, et al.
The Lancet. Oncology
|
March 4, 2014
Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study
James Larkin, Michele Del Vecchio, Paolo A Ascierto, et al.
Page
of 10
Search research articles
Search
Showing results (41-50 of 92) with videos related to
Sort By:
Page
of 10
Lancet (London, England)
|
August 21, 2017
Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)
Jacob Schachter, Antoni Ribas, Georgina V Long, et al.
The Lancet. Oncology
|
June 22, 2019
Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study
Georgina V Long, Reinhard Dummer, Omid Hamid, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 21, 2022
COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients With <i>BRAF</i> V600-Mutant Melanoma
Reinhard Dummer, Keith T Flaherty, Caroline Robert, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 3, 2023
A Phase II Trial of the CD40 Agonistic Antibody Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Confirmed Disease Progression on Anti-PD-1 Therapy
Sarah A Weiss, Mario Sznol, Montaser Shaheen, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 23, 2019
Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management
Helen J Gogas, Keith T Flaherty, Reinhard Dummer, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 9, 2024
COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600E/K-mutant melanoma
Dirk Schadendorf, Reinhard Dummer, Keith T Flaherty, et al.
Nature Medicine
|
October 6, 2020
Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i
Reinhard Dummer, Celeste Lebbé, Victoria Atkinson, et al.
The Lancet. Oncology
|
July 27, 2019
Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study
Caroline Robert, Antoni Ribas, Jacob Schachter, et al.
JAMA Oncology
|
July 17, 2020
Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition With Pembrolizumab Outcomes in Advanced Melanoma: Pooled Analysis of 3 Clinical Trials
Igor Puzanov, Antoni Ribas, Caroline Robert, et al.
The Lancet. Oncology
|
March 4, 2014
Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study
James Larkin, Michele Del Vecchio, Paolo A Ascierto, et al.
Page
of 10